New combo targets tough stomach cancers
NCT ID NCT06947291
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This study tests a new drug (glumetinib) combined with chemotherapy in people with advanced stomach cancer or related tumors that have a specific genetic change (MET). The goal is to see if the combination can shrink tumors and control the disease. About 350 adults will take part, and the study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AND OTHER SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.